BIM
PACB icon

Bogle Investment Management’s Pacific Biosciences PACB Stock Holding History

Bogle Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-9,800
Closed -$254K – 78
2020
Q4 		$254K Buy
+9,800
New +$167K 0.4% 122
2016
Q2 		– Sell
-585,609
Closed -$4.98M – 448
2016
Q1 		$4.98M Sell
585,609
-184,149
-24% -$1.81M 0.33% 100
2015
Q4 		$10.1M Buy
+769,758
New +$6.91M 0.73% 50
2014
Q4 		– Sell
-205,514
Closed -$1.01M – 399
2014
Q3 		$1.01M Buy
205,514
+95,723
+87% +$501K 0.07% 247
2014
Q2 		$678K Sell
109,791
-469,969
-81% -$2.35M 0.05% 260
2014
Q1 		$3.1M Sell
579,760
-110,477
-16% -$698K 0.21% 148
2013
Q4 		$3.61M Buy
690,237
+564,772
+450% +$2.59M 0.3% 115
2013
Q3 		$692K Buy
+125,465
New +$436K 0.07% 245

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bogle Investment Management's PACB Position: Q1 2021 in Review

Bogle Investment Management sold out of Pacific Biosciences (PACB) in Q1 2021, closing a stake of 9,800 shares — an estimated $254K sold.

Bogle Investment Management first reported a position in PACB in Q3 2013 and held it in 8 quarters. The position peaked at $10.1M in Q4 2015. 263 funds tracked by Wall St. Rank hold PACB as of Q1 2021.

  • Bogle Investment Management reported no remaining Pacific Biosciences position as of Q1 2021 after selling out during the quarter.
  • Bogle Investment Management sold 9,800 Pacific Biosciences shares in Q1 2021, an estimated $254K.
  • Bogle Investment Management first reported a position in Pacific Biosciences in Q3 2013 and held it in 8 quarters.
  • Bogle Investment Management's Pacific Biosciences position peaked at $10.1M in Q4 2015.
  • 263 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2021.

Based on Bogle Investment Management's 13F filing for Q1 2021.